US-based clinical-stage biotechnology company Novavax has selected Australian speciality laboratory 360biolabs to conduct sample analysis for the clinical trial of its COVID-19 recombinant spike protein nanoparticle vaccine (NVX-CoV2373).
A specialist biosecurity facility is required for the trial. “We are thrilled that an organisation with the reputation and capabilities of 360biolabs agreed to work with us in this critical clinical trial,” said Gregory Glenn, Novavax President of Research and Development. “We are confident 360biolabs will provide timely and appropriate data results.”
360biolabs said it is Australia’s only ISO accredited clinical services organisation currently working with COVID-19. The Phase 1 trial of NVX-CoV2373 is expected to begin this month with preliminary immunogenicity and safety results in July.